What is iFyber?
iFyber operates as a preclinical contract research organization (CRO) that excels in custom method development by harmonizing chemistry, biology, and materials science. The company provides a comprehensive suite of services, including microbial control, biofilm testing, and antimicrobial efficacy testing, alongside various analytical services. iFyber primarily serves clients within the medical device, wound care, diagnostics, and specialty textiles industries, offering tailored expertise to support their research and development initiatives.
How much funding has iFyber raised?
iFyber has raised a total of $378K across 2 funding rounds:
Debt
$150K
Debt
$228K
Debt (2020): $150K with participation from PPP
Debt (2021): $228K led by PPP
What's next for iFyber?
The substantial capital infusion, characterized as large-scale late-stage funding and a major strategic investment, positions iFyber for significant expansion and innovation. This financial backing is likely to accelerate the development of new service offerings, enhance its research capabilities, and potentially broaden its market reach. The company's focus on integrating diverse scientific disciplines suggests a strategic approach to addressing complex challenges in preclinical research, aiming to solidify its role as a key partner for companies in the life sciences and advanced materials sectors.
See full iFyber company page
